[Therapy of paraproteinemic hemoblastoses].
Chemotherapy with alkylating agents and Prednisone can achieve a prolonged median survival time in patients with multiple myeloma which lasts as long as the remission endures. Aggressive therapeutic regimens could not achieve a further tumor cell reduction as soon as a stable phase is reached. Waldenström's macroglobulinemia requires a therapeutic approach, which is adjusted to the individual case. Patients with small tumor mass and therapy responders have a significant prolonged median survival time compared to patients with large tumor mass and non-responders.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007128:Immunoglobulin Fragments / Q000032:analysis; D007147:Immunoglobulin Light Chains / Q000032:analysis; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D010265:Paraproteinemias / Q000188:drug therapy* / Q000276:immunology; D010954:Plasmacytoma / Q000188:drug therapy / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000276:immunology
D000970:Antineoplastic Agents; D007128:Immunoglobulin Fragments; D007147:Immunoglobulin Light Chains; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan
Therapie der paraproteinämischen Hämoblastosen.